Cervical cancer is the 4th most common cancer in women worldwide. Early detection of precancer has shown to be successful in reducing cancer incidence and mortality. The Horizon 2020 CHILI project aims to translate new cervical cancer screening strategy to low-income settings. The strategy includes a new cervical cancer screening test which is currently being developed in ELEVATE (EU grant agreement No 825747), another Horizon 2020 project, and combines self-sampling with a low-cost, portable measurement device, detecting both the human papilloma virus – the main cause of cervical cancer – and cancer biomarker proteins.

Fraunhofer IMM, working in the “Microfluidic cartridge and screening tools adaptation” work package, is responsible for the development of the microfluidic cartridge and the integration of the sensor and sample preparation. Fraunhofer IMM has a wealth of experience in microfluidics and microsystem design and will be designing, prototyping and testing the microfluidic cartridges.

The entire press release about the Horizon 2020 CHILI project can be viewed here.